PAM
CRDL

PVG Asset Management’s Cardiol Therapeutics CRDL Stock Holding History

PVG Asset Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Hold
107,165
– – 0.07% 126
2026
Q1 		$113K Buy
107,165
+10,000
+10% +$10.3K 0.07% 118
2025
Q4 		$92.7K Sell
97,165
-44,932
-32% -$47.1K 0.2% 84
2025
Q3 		$152K Sell
142,097
-141,375
-50% -$172K 0.56% 62
2025
Q2 		$386K Sell
283,472
-153,890
-35% -$179K 1.31% 26
2025
Q1 		$424K Sell
437,362
-49,933
-10% -$61.3K 1.85% 15
2024
Q4 		$624K Buy
+487,295
New +$822K 2.95% 13

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PVG Asset Management's CRDL Position: Q2 2026 in Review

PVG Asset Management held its Cardiol Therapeutics (CRDL) position steady in Q2 2026 at 107,165 shares worth $114K. The position accounts for 0.07% of the portfolio, ranked #126.

PVG Asset Management first reported a position in CRDL in Q4 2024 and has held it in 7 quarters since. The position peaked at $624K in Q4 2024. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • PVG Asset Management held 107,165 shares of Cardiol Therapeutics worth $114K as of Q2 2026.
  • PVG Asset Management left its Cardiol Therapeutics share count unchanged in Q2 2026.
  • Cardiol Therapeutics made up 0.07% of PVG Asset Management's portfolio in Q2 2026, its #126 holding.
  • PVG Asset Management first reported a position in Cardiol Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • PVG Asset Management's Cardiol Therapeutics position peaked at $624K in Q4 2024.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on PVG Asset Management's 13F filing for Q2 2026, filed 1 Jul 2026.